Scientists Gather to Discuss Novel Uses of Caliper Life Sciences' Discovery Platforms...

Scientists Gather to Discuss Novel Uses of Caliper Life Sciences' Discovery
Platforms and Technology

- Recent 'Innovation for Experimentation' Series Attracts Over 350 Attendees -

HOPKINTON, Mass., June 29 /PRNewswire-FirstCall/ -- Caliper Life Sciences,
Inc. (Nasdaq: CALP), a leading provider of tools and services for drug
discovery and life sciences research, reports that more than 350 customers
recently attended its "Innovation for Experimentation" seminar series and open
house events held in California and Massachusetts. The seminar series
showcased how customers were successfully deploying technologies from Caliper
to accelerate drug discovery research.

The events were held in San Francisco, San Diego and Hopkinton to discuss the
importance of Caliper's automation, microfluidics, and in vivo imaging
technologies. Key themes included approaches for obtaining higher fidelity
data that better predict human outcomes, increasing throughput and unattended
run time while being cognizant of optimizing higher order workflows,
decentralizing testing to ensure information is available in real time to
decision makers, and increasing the knowledge generated per dollar, hour, and
number of samples.

"The life sciences industry is tasked with the noble mission of finding cures
and treatments for the sick and suffering," said Kevin Hrusovsky, CEO of
Caliper Life Sciences. "Our symposium series 'Innovation for Experimentation'
enables us to better align our internal research priorities and investments
with customer requirements to ensure that we develop technologies that enable
our customers to be successful in increasing the quality and length of life.
This year's series was the best attended in years primarily due to our new
comprehensive suite of 'breakthrough' LabChip, IVIS and Zephyr platforms."

The events featured customer presentations focused on the adoption of Caliper
platforms to accelerate discovery research at the following institutions:
Pfizer, Merck, EMD Serono, Amgen, ArQule, Dana Farber Cancer Institute,
Boehringer-Ingelheim, Wyeth, Calloway Labs, University of Massachusetts,
Genencor, Bristol-Myers Squibb, XcellereX, SUNY Upstate, Vertex, Dow
Biopharma, Symbiosis, MacroGenics, Geron, Elan, Roche, and the National Cancer
Institute. The open house event in Hopkinton featured a keynote presentation
from Kevin Hrusovsky, which is available online:
http://www.caliperls.com/investors/open-house-061909-ceo-presentation.php.

Investors and analysts were also invited to attend and participate in a
separate breakout session featuring presentations by Kevin Hrusovsky,
President and CEO, as well as several members of Caliper's executive team, who
outlined Caliper's strategic priorities and the future direction of Caliper's
technologies and services. A webcast of this breakout session is available
online:
http://phx.corporate-ir.net/phoenix.zhtml?c=85833&p=irol-EventDetails&EventId=2268770.

About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies
enabling researchers in the life sciences industry to create life-saving and
enhancing medicines and diagnostic tests more quickly and efficiently. Caliper
is aggressively innovating new technology to bridge the gap between in vitro
assays and in vivo results and then translating those results into cures for
human disease. Caliper's portfolio of offerings includes state-of-the-art
microfluidics, lab automation & liquid handling, optical imaging technologies,
and discovery & development outsourcing solutions. For more information please
visit www.caliperLS.com.

Caliper, LabChip, IVIS, and Zephyr are registered trademarks of Caliper Life
Sciences, Inc.

SOURCE Caliper Life Sciences, Inc.

Tim Pitta or Stacey Holifield, both of Schwartz Communications,
+1-781-684-0770, caliper@schwartz-pr.com, for Caliper Life Sciences, Inc.